Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 3 Next >
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Combination of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.